Urinary biomarkers for prostate cancer

Francesca Giunchi, Chiara Ciccarese, Rodolfo Montironi, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Holger Moch, Francesco Massari, Michelangelo Fiorentino

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background: Urine may represent a convenient source of biomarkers for the early detection of Prostate Cancer (PCA) since it contains secreted prostatic products and exfoliated tumor cells. Furthermore, urine is easy to collect with non-invasive procedures which are repeatable. Method: Several urinary biomarkers for PCA have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation. DNA markers have been proposed but they are less suitable compared to other malignancies, such as bladder cancer due to the limited amount of DNA somatic alterations in PCA compared to gene fusions and pathway activations. Conclusion: RNA biomarkers are still the most promising and particularly miRNA and AMACR mRNA but the main weaknesses that prevented the full clinical implementation are the absence of a validated of the cut-off levels and the identification of consistent reference standards.

Original languageEnglish (US)
Pages (from-to)723-726
Number of pages4
JournalCurrent Drug Metabolism
Volume18
Issue number8
DOIs
StatePublished - Jan 1 2017

Fingerprint

Biomarkers
Prostatic Neoplasms
Urine
Gene Fusion
DNA
MicroRNAs
Genetic Markers
Early Detection of Cancer
Urinary Bladder Neoplasms
Tumors
Neoplasms
Fusion reactions
Genes
Chemical activation
Cells
RNA
Messenger RNA
Proteins

Keywords

  • Biomarkers
  • PCA3
  • Prostate
  • Prostate cancer
  • TMPRSS2-ERG fusion
  • Urinary markers

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

Giunchi, F., Ciccarese, C., Montironi, R., Scarpelli, M., Lopez-Beltran, A., Cheng, L., ... Fiorentino, M. (2017). Urinary biomarkers for prostate cancer. Current Drug Metabolism, 18(8), 723-726. https://doi.org/10.2174/1389200218666170518161140

Urinary biomarkers for prostate cancer. / Giunchi, Francesca; Ciccarese, Chiara; Montironi, Rodolfo; Scarpelli, Marina; Lopez-Beltran, Antonio; Cheng, Liang; Moch, Holger; Massari, Francesco; Fiorentino, Michelangelo.

In: Current Drug Metabolism, Vol. 18, No. 8, 01.01.2017, p. 723-726.

Research output: Contribution to journalReview article

Giunchi, F, Ciccarese, C, Montironi, R, Scarpelli, M, Lopez-Beltran, A, Cheng, L, Moch, H, Massari, F & Fiorentino, M 2017, 'Urinary biomarkers for prostate cancer', Current Drug Metabolism, vol. 18, no. 8, pp. 723-726. https://doi.org/10.2174/1389200218666170518161140
Giunchi F, Ciccarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L et al. Urinary biomarkers for prostate cancer. Current Drug Metabolism. 2017 Jan 1;18(8):723-726. https://doi.org/10.2174/1389200218666170518161140
Giunchi, Francesca ; Ciccarese, Chiara ; Montironi, Rodolfo ; Scarpelli, Marina ; Lopez-Beltran, Antonio ; Cheng, Liang ; Moch, Holger ; Massari, Francesco ; Fiorentino, Michelangelo. / Urinary biomarkers for prostate cancer. In: Current Drug Metabolism. 2017 ; Vol. 18, No. 8. pp. 723-726.
@article{87473efe427c4f7b934ed7323f92467c,
title = "Urinary biomarkers for prostate cancer",
abstract = "Background: Urine may represent a convenient source of biomarkers for the early detection of Prostate Cancer (PCA) since it contains secreted prostatic products and exfoliated tumor cells. Furthermore, urine is easy to collect with non-invasive procedures which are repeatable. Method: Several urinary biomarkers for PCA have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation. DNA markers have been proposed but they are less suitable compared to other malignancies, such as bladder cancer due to the limited amount of DNA somatic alterations in PCA compared to gene fusions and pathway activations. Conclusion: RNA biomarkers are still the most promising and particularly miRNA and AMACR mRNA but the main weaknesses that prevented the full clinical implementation are the absence of a validated of the cut-off levels and the identification of consistent reference standards.",
keywords = "Biomarkers, PCA3, Prostate, Prostate cancer, TMPRSS2-ERG fusion, Urinary markers",
author = "Francesca Giunchi and Chiara Ciccarese and Rodolfo Montironi and Marina Scarpelli and Antonio Lopez-Beltran and Liang Cheng and Holger Moch and Francesco Massari and Michelangelo Fiorentino",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/1389200218666170518161140",
language = "English (US)",
volume = "18",
pages = "723--726",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Urinary biomarkers for prostate cancer

AU - Giunchi, Francesca

AU - Ciccarese, Chiara

AU - Montironi, Rodolfo

AU - Scarpelli, Marina

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Moch, Holger

AU - Massari, Francesco

AU - Fiorentino, Michelangelo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Urine may represent a convenient source of biomarkers for the early detection of Prostate Cancer (PCA) since it contains secreted prostatic products and exfoliated tumor cells. Furthermore, urine is easy to collect with non-invasive procedures which are repeatable. Method: Several urinary biomarkers for PCA have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation. DNA markers have been proposed but they are less suitable compared to other malignancies, such as bladder cancer due to the limited amount of DNA somatic alterations in PCA compared to gene fusions and pathway activations. Conclusion: RNA biomarkers are still the most promising and particularly miRNA and AMACR mRNA but the main weaknesses that prevented the full clinical implementation are the absence of a validated of the cut-off levels and the identification of consistent reference standards.

AB - Background: Urine may represent a convenient source of biomarkers for the early detection of Prostate Cancer (PCA) since it contains secreted prostatic products and exfoliated tumor cells. Furthermore, urine is easy to collect with non-invasive procedures which are repeatable. Method: Several urinary biomarkers for PCA have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation. DNA markers have been proposed but they are less suitable compared to other malignancies, such as bladder cancer due to the limited amount of DNA somatic alterations in PCA compared to gene fusions and pathway activations. Conclusion: RNA biomarkers are still the most promising and particularly miRNA and AMACR mRNA but the main weaknesses that prevented the full clinical implementation are the absence of a validated of the cut-off levels and the identification of consistent reference standards.

KW - Biomarkers

KW - PCA3

KW - Prostate

KW - Prostate cancer

KW - TMPRSS2-ERG fusion

KW - Urinary markers

UR - http://www.scopus.com/inward/record.url?scp=85035344540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035344540&partnerID=8YFLogxK

U2 - 10.2174/1389200218666170518161140

DO - 10.2174/1389200218666170518161140

M3 - Review article

VL - 18

SP - 723

EP - 726

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 8

ER -